Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 study of S-888711 in thrombocytopenic patients with chronic liver disease

Next Previous
Trial Profile

Phase 3 study of S-888711 in thrombocytopenic patients with chronic liver disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lusutrombopag (Primary)
  • Indications Thrombocytopenia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms L-PLUS1
  • Sponsors Shionogi

Most Recent Events

  • 30 Jun 2023 According to a Shionogi media release, the Mulpleta (Lusutrombopag), has received approval from the Center for Drug Evaluation, NMPA for treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.
  • 19 May 2020 Results of post hoc analysis assessing the efficacy and safety of lusutrombopag in patients undergoing a GI procedure published in Gastroenterology in conjunction with Digestive Disease Week 2020
  • 11 Dec 2019 According to a Shionogi media release, the company today announce that the National Institute for Health and Care Excellence (NICE) and Scottish Medicines Consortium (SMC) have published positive appraisals recommending the use of Mulpleo (lusutrombopag) by the NHS in England, Wales and Scotland for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) undergoing planned invasive procedures based on L-PLUS1 and L-PLUS2

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top